A Biobank Collecting Samples From People With Malignant Hypertension
Stores biological samples from adults treated for severe, dangerously high blood pressure.
Plain-language title generated from the registry record
Registry title: Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank
Key facts
- Where
- Annecy, Bordeaux, Chalon-sur-Saône, Lyon, Paris, Strasbourg, Toulouse, Tours, and Valenciennes, FranceSee the 11 sites
Where in France
- CH d'ANNECYAnnecy, FranceTaking people
- CHU de BordeauxBordeaux, FranceTaking people
- CH de Chalon sur SaôneChalon-sur-Saône, FranceTaking people
- Hospices Civils de LyonLyon, FranceNot yet recruiting
- APHP AvicenneParis, FranceTaking people
- Hôpital Européen Georges PompidouParis, FranceTaking people
- Hôpital Paris Saint JosephParis, FranceTaking people
- CHU de StrasbourgStrasbourg, FranceTaking people
- CHU de ToulouseToulouse, FranceTaking people
- CHRU de ToursTours, FranceTaking people
- CH de ValenciennesValenciennes, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier de PAU
- Trial code
- NCT06629363
- Record updated
- 22 October 2026
- Original description
The HAMA bank is an initiative aimed at collecting, preparing, and storing biological samples from patients treated for malignant hypertension and included in the HAMA cohort. Conducted under CRB (ISO20387) conditions, this biobank serves as an essential resource for understanding the disease's pathophysiology, as well as for identifying novel biomarkers and therapeutic targetsRead full original descriptionShow less
Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank
The HAMA bank is an initiative aimed at collecting, preparing, and storing biological samples from patients treated for malignant hypertension and included in the HAMA cohort. Conducted under CRB (ISO20387) conditions, this biobank serves as an essential resource for understanding the disease's pathophysiology, as well as for identifying novel biomarkers and therapeutic targets
Inclusion: patients included in the HAMA cohort with the following critera :; Malignant hypertension according to the classic definition (Severe hypertension associated with severe hypertensive retinopathy); Severe hypertension associated with acute target organ damage due to high blood pressure.
Exclusion: Refusal to participate to the substudy " HAMA bank "; patient on chronic dialysis.